From its inception in 2006, the mission of MolecularMD, an ICON plc company, has been to empower therapeutic/diagnostic co-development with strategies that mitigate risk and that nimbly adapt to accelerated approval timelines. Learn more about what makes MolecularMD recognizable as a leader in companion diagnostics development in Clinical OMICs recent article.

Read Article